ACT-HIB

This brand name is authorized in Austria, Cyprus, Estonia, Finland, France, Hong Kong, Netherlands, New Zealand, Poland, Turkey

Active ingredients

The drug ACT-HIB contains one active pharmaceutical ingredient (API):

1 Haemophilus influenzae B UNII FLV5I5W26R - HAEMOPHILUS INFLUENZAE TYPE B STRAIN 1482 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. Read about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07AG01	Haemophilus influenzae B, purified antigen conjugated	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines
Discover more medicines within J07AG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1019584
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 198901
Country: FR	Base de données publique des médicaments	Identifier(s): 61104024
Country: HK	Department of Health Drug Office	Identifier(s): 37568
Country: NL	Z-Index G-Standaard	Identifier(s): 13901397
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 36471
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 6803
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100224400
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699625960022